Stockreport

Collegium Pharmaceutical: Buying The Projected Growth For 2026 [Seeking Alpha]

Collegium Pharmaceutical, Inc.  (COLL) 
Last collegium pharmaceutical, inc. earnings: 2/27 04:01 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.collegiumpharma.com
PDF COLL's growth is shifting from Xtampza ER to Jornay PM, which is expected to drive $190M–$200M in 2025 revenue and deeper ADHD market penetration. The pain portfolio [Read more]